Skip to main content
TORII PHARMACEUTICAL CO., LTD. logo

TORII PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4551 ISIN · JP3635800000 T Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2024-03-27 Governance Information
Country JP Japan
Listing T 4551

About TORII PHARMACEUTICAL CO., LTD.

https://www.torii.co.jp/en/

Torii Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and marketing of prescription drugs. The company's primary focus is on therapeutic agents for renal diseases and hemodialysis, particularly for chronic kidney disease (CKD). Its portfolio also includes products for skin diseases, HIV, and allergies. Torii Pharmaceutical utilizes strategic partnerships and promotes medical products from its parent company, Japan Tobacco, to provide specialized pharmaceutical solutions.

Recent filings

Filing Released Lang Actions
内部統制報告書－第132期(2023/01/01－2023/12/31)
Governance Information Classification · 100% confidence The document explicitly states in the header section ("【提出書類】") that it is an "内部統制報告書" (Internal Control Report) based on Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act ("金融商品取引法第24条の４の４第１項"). Section 1 discusses the basic framework for internal controls over financial reporting, and Section 3 concludes that the internal controls are effective as of the end of the business year (December 31, 2023). This content aligns perfectly with the requirements for an Internal Control Report, which is often filed alongside the Annual Report (10-K) but is a distinct regulatory filing focusing solely on internal controls over financial reporting. Given the specific Japanese regulatory context and the content, this is best classified as a specialized report related to financial integrity, which falls under the scope of Audit Report / Information (AR) or potentially a specific regulatory filing. However, since the document is the *report itself* detailing the assessment of internal controls, and not just an announcement of its publication, and considering the available codes, 'AR' (Audit Report / Information) is the closest fit for a comprehensive report on financial integrity/controls, although a more specific code for 'Internal Control Report' would be ideal if available. Since 'AR' covers 'applied accounting principles, and results of internal or regulatory stress tests', an internal control assessment fits within this scope better than other options. The document length is substantial, confirming it is the report, not just an announcement (ruling out RPA/RNS based on the 'MENU VS MEAL' rule).
2024-03-27 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (813 characters) and contains Japanese text indicating it is a '確認書' (Confirmation Document) submitted to the Kanto Local Finance Bureau Director ('関東財務局長') based on Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act. The core content confirms that the President, Matsuoka Goichi, has verified the appropriateness of the contents of the company's 132nd period Annual Securities Report ('有価証券報告書') for the fiscal year ending December 31, 2023. This type of document, which confirms the accuracy of a primary filing (like a 10-K equivalent, which is the '有価証券報告書' in Japan) without being the report itself, often falls under general regulatory announcements or specific confirmation filings. Given the provided definitions, this is a specific regulatory confirmation related to the annual filing process. Since there is no direct match for a 'Confirmation of Annual Report Accuracy' document, and it is a formal regulatory submission confirming compliance, it best fits the general 'Regulatory Filings' category (RNS) or potentially a specific type of Audit/Regulatory report confirmation. However, based on the 'MENU VS MEAL' rule, if this were an announcement *about* the main report, RPA or RNS would apply. Since this is a formal, required confirmation document related to the annual filing, and it is not the 10-K itself, RNS (Regulatory Filings) is the most appropriate fallback for a specific, non-standard regulatory submission that isn't a standard report (10-K, IR, ER, etc.). The presence of the term '有価証券報告書' (Annual Securities Report) confirms the context is annual reporting, but the document itself is the confirmation, not the report. FY 2023
2024-03-27 Japanese
有価証券報告書－第132期(2023/01/01－2023/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains comprehensive financial statements, business descriptions, and management information for the fiscal year ending December 31, 2023. The header explicitly identifies it as a 'Securities Report' (有価証券報告書) filed under the Financial Instruments and Exchange Act. FY 2023
2024-03-27 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO of Torii Pharmaceutical Co., Ltd., confirming the accuracy of the contents of the quarterly report for the third quarter of the 132nd fiscal period. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS). Q3 132
2023-11-01 Japanese
四半期報告書－第132期第3四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Torii Pharmaceutical Co., Ltd. in accordance with the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, including the balance sheet and income statement for the third quarter of the 132nd fiscal period (January 1, 2023, to September 30, 2023). As it provides comprehensive financial data and analysis for an interim period, it is classified as an Interim/Quarterly Report. 9M 2023
2023-11-01 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, Article 24-4-8, Paragraph 1. This is a standard Japanese regulatory filing that accompanies a quarterly report to confirm the accuracy of the financial statements. Since it is a specific regulatory filing required by law that does not fit into the primary financial report categories (like 10-K or IR) and is not merely an announcement of a report, it falls under the general regulatory filings category.
2023-08-01 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.